NYLIM
IMVT icon

New York Life Investment Management’s Immunovant IMVT Stock Holding History

New York Life Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,438
Closed -$945K – 1426
2023
Q4 		$945K Sell
22,438
-482
-2% -$17.7K 0.01% 672
2023
Q3 		$880K Sell
22,920
-3,652
-14% -$82.5K 0.01% 648
2023
Q2 		$504K Sell
26,572
-3,499
-12% -$65.3K 0.01% 716
2023
Q1 		$466K Sell
30,071
-72,884
-71% -$1.26M 0.01% 1102
2022
Q4 		$1.83M Buy
102,955
+11,612
+13% +$146K 0.02% 538
2022
Q3 		$510K Buy
91,343
+6,708
+8% +$32.8K 0.01% 724
2022
Q2 		$330K Buy
+84,635
New +$366K ﹤0.01% 1120

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

New York Life Investment Management's IMVT Position: Q1 2024 in Review

New York Life Investment Management sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 22,438 shares — an estimated $945K sold.

New York Life Investment Management first reported a position in IMVT in Q2 2022 and held it in 7 quarters. The position peaked at $1.83M in Q4 2022. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • New York Life Investment Management reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 22,438 Immunovant shares in Q1 2024, an estimated $945K.
  • New York Life Investment Management first reported a position in Immunovant in Q2 2022 and held it in 7 quarters.
  • New York Life Investment Management's Immunovant position peaked at $1.83M in Q4 2022.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.